RU2016110848A3 - - Google Patents

Download PDF

Info

Publication number: RU2016110848A3
Authority: RU; Russia

Application number

RU2016110848A

Other versions

RU2712559C2 (ru

RU2016110848A (ru

RU2712559C9 (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-28

Filing date

2014-08-28

Publication date

2018-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52587489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016110848(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-28 Application filed filed Critical

2018-11-27 Publication of RU2016110848A3 publication Critical patent/RU2016110848A3/ru

2018-11-27 Publication of RU2016110848A publication Critical patent/RU2016110848A/ru

2020-01-29 Publication of RU2712559C2 publication Critical patent/RU2712559C2/ru

2020-10-08 Application granted granted Critical

2020-10-08 Publication of RU2712559C9 publication Critical patent/RU2712559C9/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

RU2016110848A 2013-08-28 2014-08-28 Модуляция экспрессии прекалликреина (пкк) RU2712559C9 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361871175P	2013-08-28	2013-08-28
US61/871,175		2013-08-28
PCT/US2014/053266 WO2015031679A2 (en)	2013-08-28	2014-08-28	Modulation of prekallikrein (pkk) expression

Publications (4)

Publication Number	Publication Date
RU2016110848A3 true RU2016110848A3 (ru)	2018-11-27
RU2016110848A RU2016110848A (ru)	2018-11-27
RU2712559C2 RU2712559C2 (ru)	2020-01-29
RU2712559C9 RU2712559C9 (ru)	2020-10-08

Family

ID=52587489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2016110848A RU2712559C9 (ru)	2013-08-28	2014-08-28	Модуляция экспрессии прекалликреина (пкк)

Country Status (14)

Country	Link
US (5)	US9670492B2 (ru)
EP (2)	EP3038627B1 (ru)
JP (2)	JP6652922B2 (ru)
KR (1)	KR102365486B1 (ru)
CN (1)	CN105517556B (ru)
AU (2)	AU2014312196C1 (ru)
BR (1)	BR112016004093A2 (ru)
CA (1)	CA2921839A1 (ru)
ES (1)	ES2790574T3 (ru)
IL (1)	IL244047A0 (ru)
MX (1)	MX2016002587A (ru)
NZ (1)	NZ716816A (ru)
RU (1)	RU2712559C9 (ru)
WO (1)	WO2015031679A2 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2790574T3 (es)	2013-08-28	2020-10-28	Ionis Pharmaceuticals Inc	Modulación de expresión de prekallikrein (PKK)
DK3137091T3 (da)	2014-05-01	2021-01-25	Ionis Pharmaceuticals Inc	Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
JP7319916B2 (ja)	2016-09-16	2023-08-02	武田薬品工業株式会社	遺伝性血管性浮腫のｒｎａバイオマーカー
EP3548005A4 (en)	2016-11-29	2020-06-17	Puretech Health LLC	Exosomes for delivery of therapeutic agents
AU2018374219C1 (en)	2017-12-01	2023-05-11	Suzhou Ribo Life Science Co., Ltd.	Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
EP3718572B1 (en)	2017-12-01	2024-07-31	Suzhou Ribo Life Science Co., Ltd.	Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
CN110945132B (zh)	2017-12-01	2024-04-05	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110945130B (zh)	2017-12-01	2024-04-09	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110997917B (zh)	2017-12-01	2024-04-09	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7436030B2 (ja)	2017-12-29	2024-02-21	スーチョウリボライフサイエンスカンパニー、リミテッド	複合体及びその調製方法と使用
EP3842534A4 (en)	2018-08-21	2022-07-06	Suzhou Ribo Life Science Co., Ltd.	NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF
EP3862024A4 (en)	2018-09-30	2022-08-17	Suzhou Ribo Life Science Co., Ltd.	SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF
EP3992290A4 (en) *	2019-05-24	2023-11-15	Suzhou Ribo Life Science Co., Ltd.	NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND NUCLEIC ACID-CONTAINING CONJUGATE AND METHOD OF USE THEREOF
CN115362256A (zh) *	2020-02-07	2022-11-18	因特利亚治疗公司	用于激肽释放酶（klkb1）基因编辑的组合物和方法
CN115244179A (zh) *	2020-03-13	2022-10-25	Ionis制药公司	用于治疗和预防前激肽释放酶相关疾患的组合物和方法
WO2021248027A1 (en) *	2020-06-05	2021-12-09	Ionis Pharmaceuticals, Inc.	Compositions and methods of inhibiting angiotensin-converting enzyme 2 (ace2) and transmembrane serine protease 2 (tmprss2)
JP2023549563A (ja) *	2020-11-18	2023-11-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	アンジオテンシノーゲン発現を調節するための化合物及び方法
US20250320500A1 (en) *	2020-12-29	2025-10-16	Suzhou Ribo Life Science Co., Ltd.	Nucleic acid, pharmaceutical composition and sirna conjugate containing the nucleic acid, preparation method therefor, and use thereof
US11833221B2 (en) *	2021-09-01	2023-12-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds for reducing DMPK expression
EP4409003A1 (en)	2021-10-01	2024-08-07	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
TW202346586A (zh) *	2022-01-28	2023-12-01	大陸商上海舶望製藥有限公司	用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2699508A (en)	1951-12-21	1955-01-11	Selectronics Inc	Method of mounting and construction of mounting for low frequency piezoelectric crystals
DE2654124A1 (de)	1976-11-29	1978-06-01	Bayer Ag	Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
FR2599752B1 (fr)	1986-06-10	1989-11-03	Transgene Sa	Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE190981T1 (de)	1989-10-24	2000-04-15	Isis Pharmaceuticals Inc	2'-modifizierte nukleotide
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ATE167523T1 (de)	1990-05-11	1998-07-15	Microprobe Corp	Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
US6582908B2 (en)	1990-12-06	2003-06-24	Affymetrix, Inc.	Oligonucleotides
ES2103918T3 (es)	1991-10-17	1997-10-01	Ciba Geigy Ag	Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
EP1044987B1 (en) *	1991-12-24	2006-02-15	Isis Pharmaceuticals, Inc.	Gapped 2'-modified oligonucleotides
FR2687679B1 (fr)	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
EP0577558A2 (de)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
EP0673559A1 (en)	1992-12-14	1995-09-27	Honeywell Inc.	Motor system with individually controlled redundant windings
ATE155467T1 (de)	1993-03-30	1997-08-15	Sanofi Sa	Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
US5801154A (en)	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
US5786328A (en)	1995-06-05	1998-07-28	Genentech, Inc.	Use of kunitz type plasma kallikrein inhibitors
US7875733B2 (en)	2003-09-18	2011-01-25	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
WO2005121371A2 (en)	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US5869637A (en)	1996-07-22	1999-02-09	Incyte Pharmaceuticals, Inc.	Human Kallikrein
US6770748B2 (en)	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
WO1999014226A2 (en)	1997-09-12	1999-03-25	Exiqon A/S	Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US20030228597A1 (en)	1998-04-13	2003-12-11	Cowsert Lex M.	Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
HK1048322A1 (zh)	1999-05-04	2003-03-28	埃克西库恩公司	L-核糖-lna类似物
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides
DE19935303A1 (de) *	1999-07-28	2001-02-08	Aventis Pharma Gmbh	Oligonukleotide zur Inhibierung der Expression von humanem eg5
US20020082227A1 (en)	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
WO2001049687A2 (en)	1999-12-30	2001-07-12	K. U. Leuven Research & Development	Cyclohexene nucleic acids
TR200401292T3 (tr) *	2000-12-01	2004-07-21	Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften	RNAÁgirişimineÁyolÁaçanÁküçükÁRNAÁmolekülleri
JP2005504020A (ja)	2001-07-03	2005-02-10	アイシス・ファーマシューティカルス・インコーポレーテッド	ヌクレアーゼ耐性キメラオリゴヌクレオチド
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040097441A1 (en) *	2002-11-16	2004-05-20	Isis Pharmaceuticals Inc.	Modulation of NIMA-related kinase 6 expression
DK2298278T3 (en)	2002-06-07	2016-02-01	Dyax Corp	Prevention and reduction of blood loss and inflammatory response
WO2004044139A2 (en)	2002-11-05	2004-05-27	Isis Parmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
US7696345B2 (en)	2002-11-05	2010-04-13	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2284266B1 (en)	2002-11-14	2013-11-06	Thermo Fisher Scientific Biosciences Inc.	siRNA targeting tp53
WO2004106356A1 (en)	2003-05-27	2004-12-09	Syddansk Universitet	Functionalized nucleotide derivatives
EP1730158A2 (en)	2003-08-06	2006-12-13	Cygene, Inc.	Methods and compositions for in vitro and in vivo use of parallel stranded hairpins and triplex structures as nucleic acid ligands
JP4731324B2 (ja)	2003-08-28	2011-07-20	武今西	Ｎ−ｏ結合性架橋構造型新規人工核酸
EP1664791A2 (en) *	2003-08-30	2006-06-07	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
US20050118625A1 (en)	2003-10-02	2005-06-02	Mounts William M.	Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US20070253949A1 (en) *	2004-02-03	2007-11-01	Stefan Golz	Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20050221354A1 (en) *	2004-02-18	2005-10-06	Wyeth	Nucleic acid arrays for monitoring expression profiles of drug target genes
WO2005083110A1 (en)	2004-02-26	2005-09-09	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with kallikrein 4 (klk4)
KR20070085113A (ko)	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
US20050287570A1 (en)	2004-05-26	2005-12-29	Wyeth	Probe arrays for expression profiling of rat genes
WO2006008002A2 (en)	2004-07-23	2006-01-26	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006047842A2 (en)	2004-11-08	2006-05-11	K.U. Leuven Research And Development	Modified nucleosides for rna interference
US20060185027A1 (en)	2004-12-23	2006-08-17	David Bartel	Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US8841259B2 (en)	2005-02-24	2014-09-23	Joslin Diabetes Center	Compositions and methods for treating vascular permeability
CN100585701C (zh)	2005-05-13	2010-01-27	松下电器产业株式会社	混合声音分离装置
DK2314594T3 (da)	2006-01-27	2014-10-27	Isis Pharmaceuticals Inc	6-modificerede bicykliske nukleinsyreanaloger
US8178503B2 (en) *	2006-03-03	2012-05-15	International Business Machines Corporation	Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
DK2066684T3 (da)	2006-05-11	2012-10-22	Isis Pharmaceuticals Inc	5´-Modificerede bicycliske nukleinsyreanaloge
EP2051707B1 (en)	2006-07-31	2013-07-17	Activesite Pharmaceuticals, Inc.	Inhibitors of plasma kallikrein
EP2081949B1 (en)	2006-09-22	2014-12-10	GE Healthcare Dharmacon, Inc.	Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
EP2125852B1 (en)	2007-02-15	2016-04-06	Ionis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
AU2008260277C1 (en)	2007-05-30	2014-04-17	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en)	2007-06-08	2008-12-18	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
ATE538127T1 (de)	2007-07-05	2012-01-15	Isis Pharmaceuticals Inc	6-disubstituierte bicyclische nukleinsäureanaloga
AU2008289005A1 (en)	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
AU2008288772A1 (en)	2007-08-23	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
US8095862B2 (en)	2007-10-10	2012-01-10	International Business Machines Corporation	End-to-end cyclic redundancy check protection for high integrity fiber transfers
US8546556B2 (en)	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
CA2717045C (en) *	2008-03-13	2018-04-10	Celera Corporation	Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
JP5288456B2 (ja) *	2008-08-08	2013-09-11	富士フイルム株式会社	口腔扁平上皮癌の検出方法
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
JP2013516389A (ja)	2009-01-06	2013-05-13	ダイアックスコーポレーション	カリクレイン阻害剤による粘膜炎治療
WO2011017521A2 (en)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
US8609866B2 (en)	2009-12-18	2013-12-17	Activesite Pharmaceuticals, Inc.	Prodrugs of inhibitors of plasma kallikrein
HUE039605T2 (hu)	2010-01-06	2019-01-28	Dyax Corp	Plazma kallikreint kötõ proteinek
US9187749B2 (en)	2011-06-10	2015-11-17	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
EP2717923B1 (en)	2011-06-10	2017-09-27	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
US9322021B2 (en)	2011-06-29	2016-04-26	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013188876A2 (en)	2012-06-15	2013-12-19	Joslin Diabetes Center, Inc.	Methods for modulating kallikrein (klkb1) expression
ES2790574T3 (es)	2013-08-28	2020-10-28	Ionis Pharmaceuticals Inc	Modulación de expresión de prekallikrein (PKK)
DK3137091T3 (da)	2014-05-01	2021-01-25	Ionis Pharmaceuticals Inc	Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
CN115244179A (zh)	2020-03-13	2022-10-25	Ionis制药公司	用于治疗和预防前激肽释放酶相关疾患的组合物和方法

2014
- 2014-08-28 ES ES14839032T patent/ES2790574T3/es active Active
- 2014-08-28 JP JP2016537862A patent/JP6652922B2/ja active Active
- 2014-08-28 EP EP14839032.1A patent/EP3038627B1/en active Active
- 2014-08-28 EP EP20160673.8A patent/EP3715457A3/en active Pending
- 2014-08-28 BR BR112016004093A patent/BR112016004093A2/pt active Search and Examination
- 2014-08-28 WO PCT/US2014/053266 patent/WO2015031679A2/en not_active Ceased
- 2014-08-28 NZ NZ716816A patent/NZ716816A/en unknown
- 2014-08-28 RU RU2016110848A patent/RU2712559C9/ru active
- 2014-08-28 CN CN201480046661.6A patent/CN105517556B/zh active Active
- 2014-08-28 KR KR1020167007351A patent/KR102365486B1/ko active Active
- 2014-08-28 US US14/915,039 patent/US9670492B2/en active Active
- 2014-08-28 MX MX2016002587A patent/MX2016002587A/es unknown
- 2014-08-28 CA CA2921839A patent/CA2921839A1/en not_active Abandoned
- 2014-08-28 AU AU2014312196A patent/AU2014312196C1/en active Active
2016
- 2016-02-09 IL IL244047A patent/IL244047A0/en unknown
2017
- 2017-04-11 US US15/484,858 patent/US10100310B2/en active Active
2018
- 2018-09-07 US US16/125,159 patent/US11053500B2/en active Active
2019
- 2019-07-11 AU AU2019204977A patent/AU2019204977A1/en not_active Abandoned
2020
- 2020-01-24 JP JP2020009600A patent/JP2020072732A/ja active Pending
2021
- 2021-07-02 US US17/367,096 patent/US11840686B2/en active Active
2023
- 2023-10-18 US US18/489,316 patent/US20240318183A1/en active Pending

Also Published As

Publication number	Publication date
EP3715457A3 (en)	2020-12-16
AU2014312196B2 (en)	2019-04-18
US20190233827A1 (en)	2019-08-01
AU2014312196C1 (en)	2019-12-19
BR112016004093A2 (pt)	2017-10-17
EP3038627A2 (en)	2016-07-06
RU2712559C2 (ru)	2020-01-29
US20170314026A1 (en)	2017-11-02
NZ716816A (en)	2022-05-27
US10100310B2 (en)	2018-10-16
RU2016110848A (ru)	2018-11-27
EP3715457A2 (en)	2020-09-30
HK1225639A1 (en)	2017-09-15
US9670492B2 (en)	2017-06-06
JP2020072732A (ja)	2020-05-14
ES2790574T3 (es)	2020-10-28
EP3038627B1 (en)	2020-03-04
US20220170023A1 (en)	2022-06-02
WO2015031679A2 (en)	2015-03-05
AU2014312196A1 (en)	2016-03-03
WO2015031679A3 (en)	2015-05-14
US20240318183A1 (en)	2024-09-26
IL244047A0 (en)	2016-04-21
US11053500B2 (en)	2021-07-06
JP2016533751A (ja)	2016-11-04
KR102365486B1 (ko)	2022-02-18
CN105517556B (zh)	2021-02-02
US11840686B2 (en)	2023-12-12
RU2712559C9 (ru)	2020-10-08
AU2019204977A1 (en)	2019-08-01
CN105517556A (zh)	2016-04-20
US20170002359A1 (en)	2017-01-05
JP6652922B2 (ja)	2020-02-26
MX2016002587A (es)	2017-02-20
CA2921839A1 (en)	2015-03-05
KR20160048119A (ko)	2016-05-03
EP3038627A4 (en)	2017-05-17

Publication	Publication Date	Title
AP2016009275A0 (ru)	2016-06-30
BR112015007533A2 (ru)	2017-08-22
BR102016010778A2 (ru)	2017-08-08
BR112014017733A2 (ru)	2017-06-20
BR112014018502A2 (ru)	2017-06-20
BR112014017739A2 (ru)	2017-06-20
BR112014019326A2 (ru)	2017-06-20
BR112014018480A2 (ru)	2017-06-20
BR112014018516A2 (ru)	2017-06-20
BR112014020341A2 (ru)	2017-06-20
BR112014017855A2 (ru)	2017-06-20
BR112014017765A2 (ru)	2017-06-20
BR112014017669A2 (ru)	2017-06-20
BR112014021878A2 (ru)	2017-06-20
BR112014018468A2 (ru)	2017-06-20
BR112014017901A2 (ru)	2017-06-20
BR112014019204A2 (ru)	2017-06-20
BR112014018207A2 (ru)	2017-06-20
BR112015015948A2 (ru)	2017-08-15
BR112014017722A2 (ru)	2017-06-20
BR112014017653A2 (ru)	2017-06-20
BR112014018578A2 (ru)	2017-06-20
BR112014018483A2 (ru)	2017-06-20
BR112014017794A2 (ru)	2017-06-20
BR112014017601A2 (ru)	2017-06-20

Legal Events

Date	Code	Title	Description
2020-10-08	TH4A	Reissue of patent specification